A Phase II Trial of Adjuvant Paclitaxel and Trastuzumab for Node-Negative HER2-Positive Breast Cancer.
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 02 Jun 2017
At a glance
- Drugs Paclitaxel (Primary) ; Trastuzumab (Primary)
- Indications Breast cancer
- Focus Therapeutic Use
- Acronyms APT Trial
- 07 Jun 2017 Biomarkers information updated
- 02 Jun 2017 Results of seven year follow up presented at the 53rd Annual Meeting of the American Society of Clinical Oncology.
- 25 May 2017 Data from this trial will be presented at the 53rd Annual Meeting of the American Society of Clinical Oncology (ASCO), as reported in a NanoString Technologies media release.